Studied since the early 1990s for gut healing, tendon repair, and systemic recovery, BPC-157 has never been placed on the formal Category 1 list yet it has one of the most extensive safety records in the peptide literature
Apart from characteristics noted in the study designs, baseline traits including age, race, and gender were similar among all of the SURPASS trials and did not impact outcomes [42, 44,45,46,47]
The unique abilities of FAAs compared to protein-bound AAs and the relatively inefficient proteolytic capacity of neonates underline the importance of understanding the FAA composition in human milk, separate from the TAA composition
The honest status of AHK-Cu is a copper tripeptide with one ex-vivo / in-vitro study, a plausible mechanism borrowed from GHK-Cu, and no human data by any route [1] [2]
The three-way comparison of semaglutide, tirzepatide, and retatrutide provides context on how these medications differ in mechanism, efficacy, and expected pricing